ureaplasma urealyticum and mycoplasma hominis colonization and chronic lung disease in preterm neonates under ventilation

background ureaplasma urealyticum (u. urealyticum) and mycoplasma hominis (m. hominis) are two important pathogens in neonatal respiratory tract infections. as low gestational age and birth weight increase the colonization rate with these pathogens, and they are also risk factors of chronic lung disease (cld), it is difficult to establish a statistically significant relation between these two factors. conclusions intrauterine infection with u. urealyticum and m. hominis leads to negative neonatal outcome and increased rate of chronic lung disease in preterm neonates (< 35 weeks). results from 62 cultures, 7 were positive for u. urealyticum (11.3%, ci95%: 3.4-19.2%) and 3 were positive for m. hominis (4.8%, ci95%: 0-10.2%). from 53 neonates who were alive at 28 days after birth, 11 neonates needed oxygen (20.8%, ci95%: 9.8-31.7%). from 10 neonates with positive cultures, 2 (20%, ci95%: 0-44.8%) died, and from 8 alive neonates, 3 (37.5%, ci95%: 4.0-71.0%) survived without cld. from 52 neonates with negative cultures, 7 (13.5%, ci95%: 4.2-22.7%) died, and from 45 alive neonates, 39 (86.7%, ci95%: 76.7-96.6%) survived without cld, and there was a significant difference between neonatal groups with positive and negative tracheal culture progressing to cld (62.5% vs. 13.3%) (p < 0.001) (figure 1). objectives to determine the colonization rate of preterm ventilated neonates with u. urealyticum and m. hominis , and the relationship between infection and chronic lung disease in these neonates, a prospective study was performed. patients and methods determining tracheal colonization rate of preterm neonates with ureaplasma and mycoplasmsa and its relation to cld. in a cohort prospective study in hazrat rasoul akram hospital, with 62 ventilated neonates (< 35 weeks) in the first 24 h of life, where tracheal secretions were aspirated, transported, and cultured in a specific media. cld was diagnosed as oxygen requirement at 28 days or 36 weeks post conceptional age.